Three vials filled with human leukocyte interferon.
Find information on thousands of medical conditions and prescription drugs.

Interferon gamma

Interferons (IFNs) are natural proteins produced by the cells of the immune systems of most animals in response to challenges by foreign agents such as viruses, bacteria, parasites and tumor cells. Interferons belong to the large class of glycoproteins known as cytokines. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Types

In humans, there are 3 major classes of interferon (IFN):

  1. The human type I IFNs consists of 13 different alpha isoforms (subtypes with slightly different specificities) - IFNA(1,2,4,5,6,7,8,10,13,14,16,17,21), and single beta - IFNB1, omega - IFNW1, epsilon - IFNE1 and kappa - IFNK isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals) and have been identified in birds, reptiles, amphibians and fish species. In addition to these IFNs, IFN zeta (limitin) in mice,IFN nu in cats, IFN tau in ruminants and IFN delta in pigs have been identified. All type I IFNs bind to a specific cell surface receptor complex known as IFNAR consisting of IFNAR1 and IFNAR2 chains.
  2. The type II IFNs consists of IFN gamma - IFNG, its sole member. The mature IFNG ligand is an anti-parallel homodimer, and it binds to the IFNG receptor (IFNGR) complex, which is made up of two of each IFNGR1 and IFNGR2 subunits.
  3. The recently discovered 3rd class consists of IFN-lambda with 3 different isoforms - IL29. IL28A, IL28B and signal through a receptor complex consisting of IL10R2 and IFNLR1.

While there are evidence to suggest other signaling mechanisms exist, the JAK-STAT signaling pathway is the best-characterised and commonly accepted IFN signaling pathway.

Principles

In a majority of cases, the production of interferons is induced in response to microbes such as viruses and bacteria and their products (viral glycoproteins, viral RNA, bacterial endotoxin, flagella, CpG DNA), as well as mitogens and other cytokines, for example interleukin-1, interleukin-2, interleukin-12, tumor-necrosis factor and colony-stimulating factor, that are synthesised in the response to the appearance of various antigens in the body. Their metabolism and excretion take place mainly in the liver and kidneys. They hardly pass the placenta and the blood-brain barrier.

Interferon-alpha and -beta are produced by many cell types, including T-cells and B-cells, macrophages, fibroblasts, endothelial cells, osteoblasts and others, and are an important component of the anti-viral response. They stimulate both macrophages and NK cells. Interferons -alpha and -beta are also active against tumors.

Interferon-gamma is involved in the regulation of the immune and inflammatory responses; in humans, there is only one type of interferon-gamma. It is produced in activated T-cells. Interferon-gamma has some anti-viral and anti-tumor effects, but these are generally weak; however, interferon-gamma potentiates the effects of interferon-alpha and interferon-beta. However, interferon-gamma must be released at the site of a tumor in very small doses; at this time, interferon-gamma is not very useful for treating cancer.

Read more at Wikipedia.org


[List your site here Free!]


Role of STAT1 in the permissive effect of interferon-gamma on fas-induced apoptosis of non-small cell lung cancer cells
From CHEST, 10/1/05 by J.R. Brewer

PURPOSE: One of the most lethal cancers is non-small cell lung carcinoma (NSCLC), which is resistant to chemotherapy- and irradiation-induced programmed cell death or apoptosis. Our objective is to define processes in NSCLC opposing apoptosis. Previously, we showed IFN[gamma] potently inhibits proliferation of human NSCLC A549 cells under optimal growth conditions by a process involving transcription factor STAT1. Here we investigated whether IFN[gamma] made A549 cells susceptible to activation of the death receptor FAS.

METHODS: A549 cells grown with 10% serum were treated as follows: vehicle, 10 ng/ml IFN[gamma], 70 ng/ml activating FAS antibody, or 10 ng/nd IFN[gamma] and 70 ng/ml FAS antibody. After 48 h, apoptosis was measured by DNA laddering, annexin V binding, and Western immunoblotting for PARP and caspase 3 cleavage. FAS was measured by Westerns, protein by BioRad DC assay. Cells were transfected with siRNA STAT1 using lipofectamine. Statistical significance (P < 0.05) was determined by ANOVA.

RESULTS: IFN[gamma] did not induce apoptosis of A549 cells as indexed by PARP or caspase 3 cleavage, DNA laddering, or annexin V binding. Neither did the agonistic anti-FAS antibody. However, together, they induced marked apoptosis as indexed by all 4 assays and loss of protein from culture dishes. The permissive effect of IFN[gamma] on FAS-induced apoptosis was not due to upregulation of FAS, as A549 cells expressed FAS and its expression was not affected by IFN[gamma]. To assess the role of STAT1, cells were transfected with STAT1 siRNA or lipofectamine alone (control) prior to treatment. Although STAT1 expression was down-regulated with siRNA, PARP and caspase 3 cleavage were still observed with the combination of IFN[gamma] and FAS antibody.

CONCLUSION: IFN[gamma] plays a permissive role in FAS-mediated apoptosis of NSCLC A549 cells by a process downstream of FAS and independent of STAT1. Further studies are underway to determine which STAT1-independent mechanism sensitizes A549 cells to apoptosis.

CLINICAL IMPLICATIONS: The combination of IFN[gamma] and activating FAS antibody could be a novel therapeutic strategy in the treatment of non-small cell lung cancer.

DISCLOSURE: Christopher Spradley, Product/procedure/technique that is considered research and is NOT yet approved for any purpose. The combination of IFN[gamma] and activating FAS antibody in the treatment of non-small cell lung cancer.

J. R. Brewer BA Christopher Spradley MD * Jeremy L. Nickolai BS Richard E. Winn MD George W. Booz PhD Scott & White Hospital and Clinic, Temple, TX

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Interferon gamma
Home Contact Resources Exchange Links ebay